Evidence map›Paper›PMID 39497571›Full record

ReviewBiochemistry2024

Primed for Discovery.

Allison S Walker, Jon Clardy

Abstract readReview
In one paragraph

Review in Biochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Negamycin: Nature's Forgotten Antibiotic.ACS infectious diseases · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Allison S WalkerDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee 37240, United States.ORCID 0000-0001-5666-7232
Jon ClardyDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School and Blavatnik Institute, Boston, Massachusetts 02115, United States.ORCID 0000-0003-0213-8356

Funding

Identification and characterization of gut microbial bioactive molecules that determine predisposition to autoimmune disease and atopyR01AT009708 · NCCIH · HARVARD MEDICAL SCHOOL · PI CLARDY, JON, XAVIER, RAMNIK J · 2017 to 2021
$3.3M
Machine learning approaches for the discovery, repurposing, and optimization of natural products with therapeutic potential - Supplement to support grad training of Adrian RussR35GM146987 · NIGMS · VANDERBILT UNIVERSITY · PI Allison Sara Walker · 2022 to 2026
$2.4M
NCCIH NIH HHS R01 AT009708NIGMS NIH HHS R35 GM146987
6 · The paper itself

Abstract

Antibiotics are essential components of current medical practice, but their effectiveness is being eroded by the increasing emergence of antimicrobial-resistant infections. At the same time, the rate of antibiotic discovery has slowed, and our future ability to treat infections is threatened. Among Christopher T. Walsh's many contributions to science was his early recognition of this threat and the potential of biosynthesis─genes and mechanisms─to contribute solutions. Here, we revisit a 2006 review by Walsh and co-workers that highlighted a major challenge in antibiotic natural product discovery: the daunting odds for identifying new naturally occurring antibiotics. The review described strategies to mitigate the odds challenge. These strategies have been used extensively by the natural product discovery community in the years since and have resulted in some promising discoveries. Despite these advances, the rarity of novel antibiotic natural products remains a barrier to discovery. We compare the challenge of discovering natural product antibiotics to the process of identifying new prime numbers, which are also challenging to find and an essential, if underappreciated, element of modern life. We propose that inclusion of filters for functional compounds early in the discovery pipeline is key to natural product antibiotic discovery, review some recent advances that enable this, and discuss some remaining challenges that need to be addressed to make antibiotic discovery sustainable in the future.

Indexed as

Anti-Bacterial AgentsBiological ProductsDrug DiscoveryHumansAnti-Bacterial AgentsBiological ProductsAntibiotic discoveryAntimicrobial resistanceDiscovery pipelineFunctional compoundsNatural productsPhenotypic screens

Identifiers

PMID39497571
PMCPMC11542185

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.